Brief: Actinium Announces Positive Full Data Results From The Pivotal Phase 3 Sierra Trial Of Iomab-B
18/02/2023 21:36
Feb 18 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES POSITIVE FULL DATA RESULTS FROM THE
PIVOTAL
PHASE 3 SIERRA TRIAL IN PATIENTS WITH ACTIVE, RELAPSED OR
REFRACTORY ACUTE MYELOID LEUKEMIA
* IOMAB-B MET PRIMARY ENDPOINT OF 6 MONTHS DCR WITH A HIGH
DEGREE
OF STATISTICAL SIGNIFICANCE (P<0.0001)
Source text for Eikon: ID:nPn4c1Mspa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities